title: [The effect of mosapride on quality of life in functional dyspepsia].
abstract: OBJECTIVE
  It is unknown whether the prokinetics improve the quality of life in patients with functional dyspepsia. Thus, we evaluate the effect of the mosapride, selective 5-HT4 agonist, on the symptom and life quality of patients with functional dyspepsia using the Nepean dyspepsia index-Korean version (NDI-K), a reliable and validated disease-specific quality of life questionnaire.
  
  
  METHODS
  A single, open trial was performed in 129 patients with functional dyspepsia. Patients were received mosapride 5 mg t.i.d before each meal for 4 weeks. The symptoms and quality of life were measured with the NDI-K at baseline and 4 weeks. The responsiveness of the NDI-K was evaluated by correlation with symptom scores.
  
  
  RESULTS
  All the 15 symptom scores and the dyspepsia score decreased after treatment (p<0.05). The total symptom score decreased from 60.9 +/- 25.8 to 24.7 +/- 20.4 (p=0.001). Correlations were observed between the total symptom score and the NDI-K score (r=0.47, p=0.001), and between the total symptom score and each score in 5 subscales (r=0.25-0.44, p=0.001). The NDI-K score was significantly increased in the effective group whose dyspepsia score decreased more than 50% of the score at baseline, compared with that of ineffective group. Any significant adverse effect and prolongation of QT interval were not occurred in all patients.
  
  
  CONCLUSIONS
  A prokinetic drug, mosapride improves the symptoms and the quality of life in patients with functional dyspepsia.
authors.affiliation: Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seocho-gu, Seoul, Korea.
authors.forename: Yu Kyung
authors.initials: YK
authors.lastname: Cho
authors.forename: Myung-Gyu
authors.initials: MG
authors.lastname: Choi
authors.forename: Se Hee
authors.initials: SH
authors.lastname: Kim
authors.forename: In Seok
authors.initials: IS
authors.lastname: Lee
authors.forename: Sang Woo
authors.initials: SW
authors.lastname: Kim
authors.forename: In-Sik
authors.initials: IS
authors.lastname: Chung
authors.forename: Sang Yeol
authors.initials: SY
authors.lastname: Lee
authors.forename: Suck Chei
authors.initials: SC
authors.lastname: Choi
authors.forename: Sang Young
authors.initials: SY
authors.lastname: Seol
mesh_terms: D000328:Adult; D000368:Aged; D001549:Benzamides / Q000627:therapeutic use*; D018492:Dopamine Antagonists / Q000627:therapeutic use*; D004415:Dyspepsia / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use*; D011788:Quality of Life; D011795:Surveys and Questionnaires
chemical_list: D001549:Benzamides; D018492:Dopamine Antagonists; D005765:Gastrointestinal Agents; D009025:Morpholines; C062720:mosapride